Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer
The use of low doses of cytotoxic agents continuously for prolonged periods is an alternative for the treatment of patients with metastatic breast cancer who have developed resistance to conventional chemotherapy. The combination of metronomic chemotherapy with therapeutic vaccines might increase th...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | International Journal of Breast Cancer |
| Online Access: | http://dx.doi.org/10.4061/2011/710292 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832545747647594496 |
|---|---|
| author | Jorge L. Soriano Noyde Batista Eduardo Santiesteban Mayté Lima Joaquín González Robin García Yohanka Zarza María V. López Myriam Rodríguez Jorge L. Loys Narciso Montejo Frank Aguirre Amparo Macías Ana M. Vázquez |
| author_facet | Jorge L. Soriano Noyde Batista Eduardo Santiesteban Mayté Lima Joaquín González Robin García Yohanka Zarza María V. López Myriam Rodríguez Jorge L. Loys Narciso Montejo Frank Aguirre Amparo Macías Ana M. Vázquez |
| author_sort | Jorge L. Soriano |
| collection | DOAJ |
| description | The use of low doses of cytotoxic agents continuously for prolonged periods is an alternative for the treatment of patients with metastatic breast cancer who have developed resistance to conventional chemotherapy. The combination of metronomic chemotherapy with therapeutic vaccines might increase the efficacy of the treatment. Twenty one patients with metastatic breast cancer in progression and a Karnosky index ≥60%, were treated with metronomic chemotherapy (50 mg of cyclophospamide orally daily and 2.5 mg of methotrexate orally bi-daily), in combination with five bi-weekly subcutaneous injections of 1 mg of aluminum hydroxide-precipitated 1E10 anti-idiotype MAb (1E10-Alum), followed by reimmunizations every 28 days. Five patients achieved objective response, eight showed stable disease and eight had disease progression. Median time to progression was 9,8 months, while median overall survival time was 12,93 months. The median duration of the response (CR+PR+SD) was 18,43 months (12,20–24,10 months), being higher than 12 months in 76,9% of the patients. Overall toxicity was generally mild. Metronomic chemotherapy combined with 1E10-Alum vaccine immunotherapy might be a useful therapeutic option for the treatment of metastatic breast cancer due to its potential impact on survival and patient quality of live, low toxicity and advantages of the administration. |
| format | Article |
| id | doaj-art-e359d622d6774569a92324148303fbb7 |
| institution | Kabale University |
| issn | 2090-3189 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Breast Cancer |
| spelling | doaj-art-e359d622d6774569a92324148303fbb72025-02-03T07:24:53ZengWileyInternational Journal of Breast Cancer2090-31892011-01-01201110.4061/2011/710292710292Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast CancerJorge L. Soriano0Noyde Batista1Eduardo Santiesteban2Mayté Lima3Joaquín González4Robin García5Yohanka Zarza6María V. López7Myriam Rodríguez8Jorge L. Loys9Narciso Montejo10Frank Aguirre11Amparo Macías12Ana M. Vázquez13Oncology Service, Hermanos Amejeiras Hospital, Havana 10300, CubaOncology Service, Hermanos Amejeiras Hospital, Havana 10300, CubaOncology Service, José R. López Tabrane Hospital, Matanzas 40100, CubaOncology Service, Hermanos Amejeiras Hospital, Havana 10300, CubaOncology Service, Hermanos Amejeiras Hospital, Havana 10300, CubaOncology Service, Hermanos Amejeiras Hospital, Havana 10300, CubaOncology Service, Hermanos Amejeiras Hospital, Havana 10300, CubaOncology Service, Hermanos Amejeiras Hospital, Havana 10300, CubaOncology Service, Hermanos Amejeiras Hospital, Havana 10300, CubaOncology Service, Hermanos Amejeiras Hospital, Havana 10300, CubaOncology Service, Hermanos Amejeiras Hospital, Havana 10300, CubaOncology Service, José R. López Tabrane Hospital, Matanzas 40100, CubaClinical Division, Center of Molecular Immunology, Havana 11600, CubaClinical Division, Center of Molecular Immunology, Havana 11600, CubaThe use of low doses of cytotoxic agents continuously for prolonged periods is an alternative for the treatment of patients with metastatic breast cancer who have developed resistance to conventional chemotherapy. The combination of metronomic chemotherapy with therapeutic vaccines might increase the efficacy of the treatment. Twenty one patients with metastatic breast cancer in progression and a Karnosky index ≥60%, were treated with metronomic chemotherapy (50 mg of cyclophospamide orally daily and 2.5 mg of methotrexate orally bi-daily), in combination with five bi-weekly subcutaneous injections of 1 mg of aluminum hydroxide-precipitated 1E10 anti-idiotype MAb (1E10-Alum), followed by reimmunizations every 28 days. Five patients achieved objective response, eight showed stable disease and eight had disease progression. Median time to progression was 9,8 months, while median overall survival time was 12,93 months. The median duration of the response (CR+PR+SD) was 18,43 months (12,20–24,10 months), being higher than 12 months in 76,9% of the patients. Overall toxicity was generally mild. Metronomic chemotherapy combined with 1E10-Alum vaccine immunotherapy might be a useful therapeutic option for the treatment of metastatic breast cancer due to its potential impact on survival and patient quality of live, low toxicity and advantages of the administration.http://dx.doi.org/10.4061/2011/710292 |
| spellingShingle | Jorge L. Soriano Noyde Batista Eduardo Santiesteban Mayté Lima Joaquín González Robin García Yohanka Zarza María V. López Myriam Rodríguez Jorge L. Loys Narciso Montejo Frank Aguirre Amparo Macías Ana M. Vázquez Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer International Journal of Breast Cancer |
| title | Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer |
| title_full | Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer |
| title_fullStr | Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer |
| title_full_unstemmed | Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer |
| title_short | Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer |
| title_sort | metronomic cyclophosphamide and methotrexate chemotherapy combined with 1e10 anti idiotype vaccine in metastatic breast cancer |
| url | http://dx.doi.org/10.4061/2011/710292 |
| work_keys_str_mv | AT jorgelsoriano metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer AT noydebatista metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer AT eduardosantiesteban metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer AT maytelima metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer AT joaquingonzalez metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer AT robingarcia metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer AT yohankazarza metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer AT mariavlopez metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer AT myriamrodriguez metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer AT jorgelloys metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer AT narcisomontejo metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer AT frankaguirre metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer AT amparomacias metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer AT anamvazquez metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer |